IAN E KROP
Affiliation: Harvard University
KROP I, Suter T, Dang C, Dirix L, Romieu G, Zamagni C, et al
. Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer. J Clin Oncol. 2015;33:1136-42 pubmed publisher
..Use of T-DM1 for approximately 1 year after anthracycline-based chemotherapy was feasible and generally well tolerated by patients with HER2-positive EBC, providing support for phase III trials of T-DM1 in this setting. ..
KROP I, Modi S, LoRusso P, Pegram M, Guardino E, Althaus B, et al
. Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer. Breast Cancer Res. 2016;18:34 pubmed publisher
..Although there is potential for paclitaxel to be added to T-DM1â€‰Â±â€‰pertuzumab, peripheral neuropathy was common in this heavily pretreated population. ClinicalTrials.gov NCT00951665 . Registered August 3, 2009. ..
KROP I, Mayer I, Ganju V, Dickler M, Johnston S, Morales S, et al
. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016;17:811-821 pubmed publisher
..No further investigation of pictilisib in this setting is ongoing. F Hoffmann-La Roche. ..
KROP I, Kim S, Martín A, LoRusso P, Ferrero J, Badovinac Črnjević T, et al
. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol. 2017;18:743-754 pubmed publisher
..F Hoffman-La Roche/Genentech. ..
KROP I, Beeram M, Modi S, Jones S, Holden S, Yu W, et al
. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol. 2010;28:2698-704 pubmed publisher
..6 mg/kg every 3 weeks, T-DM1 was associated with mild, reversible toxicity and substantial clinical activity in a heavily pretreated population. Phase II and III trials in patients with advanced HER2-positive breast cancer are under way. ..